查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1629834

全球糖尿病數位治療市場 - 2024-2031

Global Digital Therapeutics for Diabetes Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年，全球糖尿病數位治療市場規模達16億美元，預計2033年將達53億美元，2025-2033年預測期間複合年成長率為12.9%。

糖尿病數位療法是指一類基於證據、軟體驅動的解決方案，旨在利用數位技術、行為科學和個人化資料來預防、管理或治療糖尿病。這些解決方案旨在作為獨立療法或與藥物和胰島素等傳統療法結合使用。他們的目標是透過即時監測、行為矯正和病患教育，解決糖尿病的根本原因，如生活型態因素、藥物依從性和血糖調節，幫助病患管理病情。

由於糖尿病盛行率不斷上升以及持續疾病管理的需求，對糖尿病數位療法的需求正在顯著成長。這一成長主要得益於智慧型手機和數位健康技術的日益普及，這些技術為糖尿病等慢性病提供了經濟高效、可擴展和個人化的管理解決方案。例如，根據彼得森健康科技研究所(PHTI) 的說法，數位糖尿病管理解決方案對購買者的經濟影響取決於數位解決方案的價格以及它如何影響醫療保健利用模式和使用該解決方案的患者的支出。它假設合格用戶的採用率為 25%。

市場動態：

驅動程式和限制

糖尿病盛行率上升

糖尿病盛行率的上升極大地推動了糖尿病數位療法市場的成長，並且預計將在預測期內推動市場的發展，因為越來越多的糖尿病患者被診斷出需要新的、可擴展的和有效的治療方案。數位療法被視為管理糖尿病的有效方法，特別是隨著對遠端護理、個人化治療計劃和即時監測的需求不斷成長。

例如，根據國際糖尿病聯盟的數據，2021 年，5.366 億成年人（20-79 歲）患有糖尿病，即十分之一。預計到 2030 年，這一數字將增加至 6.428 億，到 2045 年將增至 7.837 億。 2021 年，糖尿病將導致 670 萬人死亡——每 5 秒就有 1 人死於糖尿病。 5.41 億成年人患有葡萄糖耐受性受損 (IGT)，這使他們面臨第 2 型糖尿病的高風險。這種不斷上升的盛行率凸顯了對易於使用且具有成本效益的糖尿病管理解決方案的迫切需求。

糖尿病是一種需要終身管理的慢性疾病，數位治療提供了一種持續監測和調整治療計劃的手段。數位平台和連接設備，如連續血糖監測儀 (CGM)、行動應用程式和胰島素劑量追蹤器，提供即時資料，從而實現更個人化的護理。這對於第 1 型和 2 型糖尿病族群特別有用，因為遵守治療計劃至關重要。

例如，BlueStar（由Welldoc 提供支援）是一種用於糖尿病管理的數位治療解決方案，它與胰島素劑量建議和持續血糖監測相結合，以提供個人化指導，這表明數位治療在日常糖尿病管理中日益重要。

資料隱私問題

資料隱私問題是糖尿病市場數位療法發展的重大障礙，因為它們直接影響信任、採用率和監管合規性。數位療法涉及敏感健康資料的收集和處理，例如血糖水平、胰島素劑量和生活習慣，這引起了人們對這些資訊的安全、儲存和共享的擔憂。

用於糖尿病管理的數位健康平台通常要求使用者輸入個人健康資訊，包括來自連續血糖監測儀 (CGM) 或智慧胰島素筆等設備的即時資料。這些資料高度敏感，必須極度謹慎地處理，以避免可能洩露個人健康資訊的外洩。

例如，根據 HIPAA 雜誌報導，2023 年 8 月，發現有 2,300 萬筆醫療記錄被洩露。在過去 12 個月中，平均每月有 9,989,003 筆醫療記錄被洩露。截至 2024 年 8 月 31 日的一年內，已發生 491 起資料外洩事件，涉及 500 筆或更多記錄，已知至少 58,668,002 筆記錄已外洩。目前，2024 年的平均外洩規模為 119,487 筆記錄，中位外洩規模為 4,109 筆記錄。

目錄

第1章：市場介紹和範圍

  • 報告的目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的片段
  • 按應用程式片段
  • 最終使用者的片段
  • 按地區分類的片段

第 3 章：動力學

  • 影響因素
    • 促進要素
      • 糖尿病盛行率上升
      • 不斷進步的技術
    • 限制
      • 資料隱私問題
    • 機會
    • 影響分析

第 4 章：策略洞察與產業展望

  • 市場領導者和先驅
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的知名領導者
    • 擁有成熟產品的市場領導者
  • 新興新創企業和關鍵創新者
  • CXO 觀點
  • 最新進展和突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：糖尿病市場的數位治療，依產品類型

  • 軟體解決方案
    • 行動應用程式
    • 網路為基礎的解決方案
  • 硬體解決方案
    • 穿戴式裝置
    • 連續血糖監測儀
    • 其他

第 6 章：糖尿病市場的數位治療（按應用）

  • 1 型糖尿病
  • 2 型糖尿病
  • 糖尿病前期

第 7 章：最終用戶的糖尿病市場數位治療

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他

第 8 章：糖尿病市場的數位治療，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 9 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的主要發展
  • 公司基準化分析

第 10 章：公司簡介

  • Welldoc, Inc.
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT分析
  • Omada Health Inc.
  • Glooko, Inc.
  • Azumio Inc.
  • Abbott Laboratories
  • mySugr GmbH
  • Dexcom, Inc.
  • Health2Sync
  • iHealth Labs Inc.
  • Medtronic plc

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD8884

The global digital therapeutics for diabetes market reached US$ 1.6 billion in 2023 and is expected to reach US$ 5.3 billion by 2033, growing at a CAGR of 12.9% during the forecast period 2025-2033.

Digital therapeutics for diabetes refers to a category of evidence-based, software-driven solutions designed to prevent, manage or treat diabetes, leveraging digital technology, behavioral science and personalized data. These solutions are intended to be used either as stand-alone therapies or in conjunction with traditional treatments such as medications and insulin. They aim to help patients manage their condition by addressing the root causes of diabetes, such as lifestyle factors, medication adherence and glucose regulation, through real-time monitoring, behavior modification and patient education.

The demand for digital therapeutics for diabetes is experiencing significant growth, driven by the increasing prevalence of diabetes and the need for continuous disease management. This growth is primarily fueled by the rising adoption of smartphones and digital health technologies, which provide cost-effective, scalable and personalized management solutions for chronic diseases like diabetes. For instance, according to the Peterson Health Technology Institute (PHTI), the economic impact on purchasers of digital diabetes management solutions depends on the price of the digital solution and how it affects patterns of healthcare utilization and spending for patients who use them. It assumes a 25% adoption rate among eligible users.

Market Dynamics: Drivers & Restraints

Rising prevalence of diabetes

The rising prevalence of diabetes is significantly driving the growth of the digital therapeutics for diabetes market and is expected to drive the market over the forecast period, as the increasing number of people diagnosed with diabetes necessitates new, scalable and effective treatment options. Digital therapeutics are seen as an efficient way to manage diabetes, especially with the growing demand for remote care, personalized treatment plans and real-time monitoring.

For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Diabetes is responsible for 6.7 million deaths in 2021 - 1 every 5 seconds. 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. This escalating prevalence highlights the urgent need for accessible and cost-effective diabetes management solutions.

Diabetes is a chronic condition requiring lifelong management and digital therapeutics provide a means to continuously monitor and adjust treatment plans. Digital platforms and connected devices, like continuous glucose monitors (CGMs), mobile apps, and insulin dose trackers, offer real-time data, allowing for more personalized care. This is particularly useful for the Type 1 and Type 2 diabetes populations, where adherence to treatment plans is crucial.

For instance, BlueStar (powered by Welldoc), a digital therapeutic solution for diabetes management, integrates with insulin dosing recommendations and continuous glucose monitoring to provide personalized guidance, demonstrating the growing importance of digital therapeutics in day-to-day diabetes management.

Data privacy concerns

Data privacy concerns are a significant barrier to the growth of digital therapeutics for the diabetes market, as they directly impact trust, adoption rates and regulatory compliance. Digital therapeutics involve the collection and processing of sensitive health data, such as glucose levels, insulin doses and lifestyle habits, which raises concerns regarding the security, storage and sharing of this information.

Digital health platforms for diabetes management often require users to input personal health information, including real-time data from devices like continuous glucose monitors (CGMs) or smart insulin pens. This data, being highly sensitive, must be handled with the utmost care to avoid breaches that could expose personal health information.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.

Segment Analysis

The global digital therapeutics for diabetes market is segmented based on product type, application, end-user and region.

Product Type:

The software solutions segment is expected to dominate the digital therapeutics for diabetes market share

The software solutions segment is expected to dominate the global digital therapeutics for diabetes market. Software-based solutions such as mobile apps and digital platforms allow patients to track glucose levels, insulin use, diet and physical activity, providing personalized feedback and treatment recommendations. For instance, in November 2024, PureHealth revealed a huge surge in users of Pura, the group's AI-enabled app. With over 140,000 downloads to date, Pura aims to improve quality of life and lifespans by providing individuals with personalized data, empowering them to improve their health through user-friendly tools and tailored insights.

Mobile and web-based applications are easy to use and accessible for a wide range of patients, including those in rural or underserved areas. The growing smartphone penetration is a key factor in this segment's dominance. For instance, in November 2023, Abbott launched its digital health tool, FreeStyle LibreLink app in India. The mobile app allows people who use the FreeStyle Libre system to measure their glucose readings on their mobile phones without pricking. The mobile app is compatible with iPhone and Android smartphones.

The integration of digital therapeutics software with wearable devices like continuous glucose monitors and smart insulin pens allows for seamless, continuous monitoring of diabetes. These integrations are essential for patients with Type 1 and Type 2 diabetes, who need real-time adjustments to their insulin and lifestyle. As mentioned above, Abbott's Freestyle Libre, connects with mobile apps to provide real-time glucose tracking, demonstrating the growing adoption of software solutions in diabetes management.

Geographical Analysis

North America is expected to hold a significant position in the digital therapeutics for diabetes market share

North America is expected to hold the largest market share in the global digital therapeutics for diabetes market. North America, particularly the United States, has a high diabetes prevalence, which fuels the demand for digital therapeutics solutions. For instance, according to the Centers for Disease Control and Prevention (CDC), In 2021, 29.7 million people of all ages or 8.9% of the U.S. population had been diagnosed with diabetes and the number is expected to rise as the population ages. This includes 304,000 with type 1 diabetes. 3.6 million adults aged 20 years or older or 12.3% of all U.S. adults with diagnosed diabetes and started using insulin within a year of their diagnosis.

The United States has one of the highest rates of smartphone and internet penetration globally, making it an ideal market for the adoption of digital health solutions like mobile apps and wearable devices. This technological infrastructure is pivotal for the adoption of digital therapeutics platforms that require constant connectivity for real-time data sharing and analysis. For instance, new National Telecommunications and Information Administration (NTIA) data showed 13 million more internet users in the U.S. in 2023 than in 2021.

Digital health solutions like Welldoc's BlueStar and Omada Health's digital platform for diabetes management have gained significant traction in the U.S., further solidifying North America's leadership in the space.

Asia-Pacific is growing at the fastest pace in the digital therapeutics for diabetes market

The Asia-Pacific region is experiencing the fastest growth in the digital therapeutics for diabetes market. There is a strong push towards digital health and telemedicine in countries like India, China and Australia, where smartphone penetration is rapidly increasing.

For instance, India had over 700 million active internet users aged 2 years and above as of December 2022, according to Nielsen's India Internet Report 2023. Of these, rural India accounted for 425 million users, which was almost 44% higher than the number of active internet users in urban areas, with 295 million users, providing a strong foundation for the growth of mobile-based digital therapeutics platforms.

Several APAC countries have launched initiatives to support digital health technologies. For example, China's "Healthy China 2030" plan aims to enhance healthcare infrastructure, which includes the adoption of digital health tools for chronic disease management.

Competitive Landscape

The major global players in the digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc., Medtronic plc and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital therapeutics for diabetes market report delivers a detailed analysis with 62 key tables, more than 52 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Digital Therapeutics for Diabetes Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Software Solutions*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Mobile Apps
    • 5.2.4. Web-Based Solutions
  • 5.3. Hardware Solutions
    • 5.3.1. Wearable Devices
    • 5.3.2. Continuous Glucose Monitors
    • 5.3.3. Others

6. Digital Therapeutics for Diabetes Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Type-1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type-2 Diabetes
  • 6.4. Pre-Diabetes

7. Digital Therapeutics for Diabetes Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Digital Therapeutics for Diabetes Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Welldoc, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Omada Health Inc.
  • 10.3. Glooko, Inc.
  • 10.4. Azumio Inc.
  • 10.5. Abbott Laboratories
  • 10.6. mySugr GmbH
  • 10.7. Dexcom, Inc.
  • 10.8. Health2Sync
  • 10.9. iHealth Labs Inc.
  • 10.10. Medtronic plc

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us